Astellas shells out $35M upfront to Cullgen in protein degrader development deal

Astellas is expanding its mark in the growing protein degradation space with a potential $1.9 billion deal with San Diego and Shanghai-based Cullgen.

Cullgen, which closed a $50 million Series B round in 2021 to develop its protein degradation platform and pipeline, will get an…

Advertisement — Advertise with Biotech Networks